Advancements in MPS I Treatment: From Enzyme Repla..

Erstellt neuen Artikel

15 Std - übersetzen

Advancements in MPS I Treatment: From Enzyme Replacement to Cutting-Edge Therapies | #hurler syndrome treatment market # hurler scheie syndrome market # laronidase biosimilar # mucopolysaccharidosis type 1 treatment # aldurazyme patent expiration # sanofi mucopolysaccharidosis / mps i # mucopolysaccharidosis type i market # mucopolysaccharidosis treatment # hurler scheie syndrome market forcast # mps type 1 treatment

Advancements in MPS I Treatment: From Enzyme Replacement to Cutting-Edge Therapies

Mucopolysaccharidosis Type I is a rare lysosomal storage disorder characterized by the deficiency of alpha-L-iduronidase enzyme, leading to the harmful accumulation of glycosaminoglycans throughout the body.

Gefällt mir

Kommentar